I think the most likely outcome of the Impress trial is that both the control and treatment arm are living longer than anticipated . The question is whether or not there is seperation between the groups and how much . The overall survival average has gotten so far beyond expectations that I anticipate that the groups have separated.
Not just football. The Biotech/Pharma season also begins after Labor Day . Medical Conferences / new data. Broker conferences institutional exposure . The season will end the first weekend in June ASCO which is the SuperBowl for oncology . Have a nice weekend before the opening kickoff!
By the way so we agree on basis of current valuation IDO generously partnered with Roche and your currently are not short . I also disagree with your victory lap on HyperA until we get the data at the end of the trial and if your right then I'll give you credit and I think your discount of Indoximod is far to early and currently wrong with lots of trials in combos many early reports coming soon. Not to mention your total discount of any value to the Ebola Vaccine. One other thing you called me a Moron , you said my success in this sector is due to luck, you said I don't do DD , you said I have no knowledge of science. You are wrong on all counts. But those false aquisations say much more about you than they do about me. IE If someone disagrees with you question his intelligence and his DD and success, and attribute it to luck! Your pretty sad
First you may be right regarding HyperAcute only the final results will determine that. So I believe you are premature in your claims of victory. I also believe that the majority of the mkt cap of NLNK is attributed to the IDO platform and if it turns out that the HA platform has value the price will explode on the upside! Once again good luck with your short as you know I am long!
By the way you mention "the well credentialed journalist Adam Feurstein "sharing your opinion. Well several years ago he and I argued regarding Medarex and if Ipilimumab Yervoy had any affect on Melanoma .this bright well informed journalist was wrong for years. It can and probably will happen to you.
Well quess what I've been right about seven out of eight of my picks on average over time not 100% like you and I've been investing in biotech for over twenty five years . I bought Medarex after their IPO in 1990. You don't get it you're not nearly as smart as you think. I've had arguments with others big ego guys like you and I was right and they were wrong. So best of luck
Nido you can't have a real discussion with someone who if you point out that others have a different opinion ie institution adding to their positions not selling and questioning his thesis he will call you a moron. He now tells you he's not exaggerating his posts are 100% correct . Good luck trying to point out he might might very well be completely wrong. LOL
R- T put up some money if you have many guys short the stock and then we can see how good you are. Io doubt you'll answer because your probably already so far under water that your hopping for a collapse to get even . By the way my average price is $12 and I'm long!
Funny but NLNK stock is holding up very well in this lousy market and First Eagle investments just filed that they rescently went from 5% to 10% unlike you that's real money , they must not have read your comments or maybe the're just not as smart as you! LOL